A pilot study of ruxolitinib as a front-line therapy for 12 children with secondary hemophagocytic lymphohistiocytosis

Hemophagocytic lymphohistiocytosis (HLH) is an immune-regulatory disorder characterized by excessive production of inflammatory cytokines. The treatment recommendations of the HLH- 1994 and HLH-2004 protocols have long been used in HLH therapy, but some patients still do not respond well to or have...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Qing, Wei, Ang, Ma, Hong-Hao, Zhang, Li, Lian, Hong-Yun, Wang, Dong, Zhao, Yun-Ze, Cui, Lei, Li, Wei-Jing, Yang, Ying, Wang, Tian-You, Li, Zhi-Gang, Zhang, Rui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8252948/
https://www.ncbi.nlm.nih.gov/pubmed/32732367
http://dx.doi.org/10.3324/haematol.2020.253781

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8252948/
https://www.ncbi.nlm.nih.gov/pubmed/32732367
http://dx.doi.org/10.3324/haematol.2020.253781

Ejemplares similares